TrialThe Lancet. Oncology2022

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Thomas Powles et al.PubMed ↗Publisher ↗

No numbers read from the abstract.